Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Physician Payment Reform Bill Offers Opportunity For Biopharma Input

This article was originally published in The Pink Sheet Daily

Executive Summary

Legislation to replace Medicare’s sustainable growth rate formula with value-based physician pay, being jointly developed by the Senate Finance Committee and House Ways and Means Committee, could be a vehicle for the biopharma industry to seek inclusion of drug-friendly policies. The committees released their discussion draft for SGR reform Oct. 31.

You may also be interested in...



CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel